Background {#Sec1}
==========

22q11.2 deletion syndrome (22q11.2DS) is the most common human microdeletion \[[@CR1]\] occurring with a prevalence of 1:4000 and incidence ranging from 1:2000--6395 \[[@CR2]--[@CR4]\]. This microdeletion is associated with several syndromic conditions including DiGeorge (DGS; MIM 188400), velocardiofacial (VCFS; MIM 192430), conotruncal anomaly face (CAFS or Takao syndrome; MIM 217095) and isolated outflow tract (OFT) defects of the heart \[[@CR5]--[@CR9]\]. These conditions are characterized predominantly by the presence of congenital heart defects, thymic and parathyroid hypoplasia, and craniofacial dysmorphism, including oro-facial clefting that predominates as isolated cleft palate, micrognathia and (less commonly) dental defects \[[@CR10]--[@CR13]\]. The most common deletions are phenotypically indistinguishable from each other and consist of either a 3 Mb segment spanning the low copy repeats (LCR) A-D (around 85% of cases); or a smaller 1.5 Mb deletion that spans LCR A-B seen in around 15% of cases \[[@CR14]--[@CR16]\]. A less common LCR C-D deletion of the typical 22q11.2DS region has also been identified, which is associated with a much-reduced prevalence of cardiac malformations and oro-facial clefting \[[@CR17]--[@CR19]\]. 22q11.2DS is a contiguous gene and haploinsufficient syndrome with at least 30 different genes potentially contributing to the characteristic clinical features \[[@CR20], [@CR21]\]. Amongst the genes identified as candidates for the development of 22q11.2DS, T-Box 1 (*TBX1*), which encodes a T-Box-containing transcription factor is recognised as a major determinant through its location within the 22q11 critical region \[[@CR21]--[@CR23]\], expression in organs affected within the clinical spectrum \[[@CR24]--[@CR27]\] and observations that loss of *Tbx1* function in mouse recapitulates the clinical findings seen in many DGS subjects \[[@CR23], [@CR28]--[@CR31]\]. Supporting this, *TBX1* mutation has been identified in a sporadic case of DGS \[[@CR32]\] and *Tbx1* haploinsufficiency results in the most characteristic phenotypes related to developmental defects in the embryonic pharyngeal apparatus \[[@CR32], [@CR33]\]. DGS is also referred to as the III-IV pharyngeal pouch syndrome, as the pharyngeal pouches and their associated blood vessels are the structures most commonly affected \[[@CR23], [@CR30]\]. Apart from the aortic arch, thymus and parathyroid gland defects, *Tbx1* murine models also manifest craniofacial anomalies that arise from developmental defects associated with pharyngeal arches I and II \[[@CR23], [@CR34], [@CR35]\]. Indeed, conditional mutant models have revealed a tissue-specific requirement and a dose sensitivity for *Tbx1* during murine pharyngeal development \[[@CR20], [@CR36]--[@CR38]\].

The majority of 22q11.2DS individuals have a characteristic craniofacial morphology including lateral displacement of the inner canthi, swollen eyelids, small mouth, hypoplastic mandible, flat nasal bridge and square nose \[[@CR39]--[@CR41]\]. Cleft palate (including submucous cleft) is also present in approximately 10% of subjects \[[@CR40]\]. Morphological studies to assess embryonic malformations in various *Tbx1* genotypes also reveal the presence of cleft palate in *Tbx1*-overexpressing mice \[[@CR42], [@CR43]\]. Therefore, both loss and gain of *Tbx1* function can lead to the development of a cleft phenotype.

The palate is divided anatomically into primary and secondary regions with the secondary palate composed of both hard and soft tissues. Embryologically, the secondary palate is derived from the paired maxillary processes of pharyngeal arch I, which gives rise to the palatal shelves. During palatogenesis, these shelves are initially situated bilaterally adjacent to the developing tongue; however, progressive growth and elevation results in them positioning themselves above the tongue, with further medial growth leading to fusion with their counterpart along the midline to create a single continuous palate. The palatal shelves also fuse with the nasal septum superiorly and primary palate anteriorly, completing separation of the nasal and oral cavities \[[@CR44]--[@CR46]\]. In the developing mouse embryo, *Tbx1* is expressed in epithelium of the palatal shelves throughout palatogenesis from embryonic day (E)12.5--15.5 \[[@CR24]\]. The etiological basis of the cleft palate phenotype in *Tbx1* mutants is not fully understood but has been associated with abnormal palatal shelf elevation, possibly due to a combination of increased tongue height, decreased palatal shelf width, perturbed cell proliferation and apoptosis \[[@CR47]\]. In addition, inappropriate fusion between the palatal shelf epithelium and tongue has also been described in this mutant, associated with hyper-proliferation and disrupted differentiation \[[@CR48]\]. More recently, confocal image analysis has found only subtle differences in levels of proliferation within mesenchyme of the palatal shelves between wild-type and mutant until the later stages of palatogenesis; although significant differences in mesenchymal cell orientation were found in mutant shelves, which might contribute to the cleft phenotype \[[@CR49]\].

We are interested in further defining the role of *Tbx1* during the process of murine palatogenesis. Specifically, we have investigated regulation of this transcription factor in the secondary palate and carried out a functionally-based microarray using the *Tbx1* mouse model. We compared total RNA isolated from dissected secondary palatal shelves derived from E13.5 wild type (WT), Tbx1^+/−^ (heterozygous) and *Tbx1*^*−/−*^ (mutant) embryos and clustered the data into three groups based on comparison between the three genotypes. Microarray analysis demonstrated that in the absence of functional *Tbx1*, significant changes occur in the expression profile of numerous genes in mutant versus WT and mutant versus heterozygous groups. The most significant pathways affected in both groups were the hypertrophic cardiomyopathy, cardiac muscle contraction, dilated cardiomyopathy, focal adhesion, calcium signalling and tight junction pathways. High-throughput quantitative RT-PCR validation confirmed significant variation between WT and mutant in the expression of 26 individual genes. We discuss these findings within the context of murine secondary palatogenesis.

Results {#Sec2}
=======

Regulation of Tbx1 in the developing secondary palate {#Sec3}
-----------------------------------------------------

*Tbx1* transcriptional activity is present in epithelium of the secondary palate shelves throughout the processes of growth, elevation and fusion (Additional file [1](#MOESM1){ref-type="media"}) and *Tbx1* mutant mice have a fully penetrant cleft palate \[[@CR23], [@CR30], [@CR31]\]. We are interested in further defining the function of this transcription factor during palatogenesis at the molecular level and first sought to understand how *Tbx1* transcription might be regulated in the palatal shelf epithelium. We began by investigating the effect of abrogating either Sonic hedgehog (Shh) or Fibroblast growth factor (Fgf) signaling in palatal shelf explants as there are potential associations between these signaling networks and Tbx1 function in the developing palate. *Shh* is also expressed in the palatal epithelium and lies upstream of *Tbx1* in the pharyngeal endoderm \[[@CR50]\]; whilst Fgf signaling can maintain *Tbx1* expression in early odontogenic epithelium \[[@CR27]\]. Specifically, E13.5 secondary palatal shelves were isolated and cultured for 24 h in the presence of either the Shh antagonist cyclopamine or the Fgf receptor inhibitor SU4502. Interestingly, whilst an absence of Shh signaling did not affect *Tbx1* transcription, loss of Fgf signaling resulted in a loss of *Tbx1* activity in the palatal epithelium after 24 h of culture (Fig. [1a](#Fig1){ref-type="fig"}-[g](#Fig1){ref-type="fig"}). These results place *Tbx1* downstream of Fgf signaling during early palatogenesis and in contrast to the pharyngeal region, loss of Shh does not affect *Tbx1*.Fig. 1Regulation of *Tbx1* expression in the early secondary palate. Wholemount in situ hybridization on palatal shelf explants cultured for 24 h in the presence or absence of the Shh inhibitor cyclopamine and the Fgf receptor inhibitor SU5402. **a** *Tbx1* is expressed in the palatal shelf epithelium and first molar tooth germ (arrowed); (**b**) in the absence of Shh signaling, *Tbx1* is maintained; (**c**) in the absence of Fgf signaling, *Tbx1* is lost; (**d**) Shh signaling is active in the developing palate and first molar (arrowed) as shown by expression of the Shh transcriptional target patched1 (*Ptch1*); (**e**) in the presence of cyclopamine *Ptch1* transcription is lost; (**f**) Fgf signaling is active in the developing palate and first molar (arrowed), as shown by expression of the Fgf transcriptional target sprouty2 (*Spry2*); (**g**) in the presence of SU4502 *Spry2* is lost. Lines mark the medial edge of the palatal shelf

Altered gene expression in the secondary palate of Tbx1 mutant mice {#Sec4}
-------------------------------------------------------------------

It is known that Shh, Fgf and Bone morphogenetic protein (Bmp) signaling pathways are important during normal development of the palate \[[@CR51]--[@CR53]\]; in particular, reciprocal signaling between epithelial Shh and mesenchymal *Fgf10*, mediated through fibroblast growth factor receptor 2b (Fgfr2b), regulates cell proliferation in the mesenchyme \[[@CR54]\]. Whilst Shh also negatively regulates *Bmp4* in the mesenchyme, which is itself upstream of Fgf10 \[[@CR55]\]. Tbx1 interacts with a number of these molecules during embryogenesis, being directly upstream of *Fgf10* in the early heart field \[[@CR28], [@CR56]\]; negatively modulating Bmp4 through the binding of Smad1 in cardiomyocytes \[[@CR36]\] and being downstream of Shh in endoderm of the early pharynx \[[@CR50]\]. Within the palate itself, it has been variously suggested that Tbx1 negatively regulates *Fgf10* and *Bmp4*, whilst positively regulating *Fgf8* and *Pax9*, although there is currently not a consensus on these findings \[[@CR47], [@CR48]\].

Although we could find no evidence that *Tbx1* is downstream of Shh signaling in the palatal epithelium, there is considerable overlap of expression. We therefore investigated known targets of Shh within palatal shelves WT and mutant for *Tbx1* using in situ hybridization. Interestingly, we found no significant differences in expression of *Shh*, *Fgf10* and *Fgfr2b* between WT and mutant (Fig. [2a](#Fig2){ref-type="fig"}-[f](#Fig2){ref-type="fig"}). However, whilst *Fgf8* expression was also normal in the mutant shelves (Fig. [2g](#Fig2){ref-type="fig"}-[h](#Fig2){ref-type="fig"}), *Bmp4* and paired-box 9 (*Pax9)* were slightly up and downregulated, respectively in the posterior region of the secondary palate (Fig. [2i](#Fig2){ref-type="fig"}-[l](#Fig2){ref-type="fig"}). These apparent changes in *Bmp4* and *Pax9* expression in the mutant might simply be a function of altered numbers of cells expressing these genes in the palate mesenchyme, particularly as the *Tbx1* domain within the palatal epithelium does not completely overlie those of *Bmp4* or *Pax9* in the mesenchyme \[[@CR48]\]. However, given the evidence of retarded growth in *Tbx1* mutant palatal shelves \[[@CR47], [@CR48]\] if an alteration in cell number is responsible for any of these changes, it would seem to be more likely for *Pax9*.Fig. 2Signaling interactions during development of the secondary palate in WT and *Tbx1* mutant embryos. Section in situ hybridization demonstrating the expression of key signaling molecules. **a**, **b** *Shh*; (**c**, **d**) *Fgf10*; (**e**, **f**) *Fgfr2b*; (**g**, **h**) *Fgf8*; (**i**, **j**) *Bmp4*; (**k**, **l**) *Pax9*

Microarray analysis {#Sec5}
-------------------

To further identify potential transcriptional target genes of Tbx1 implicated in palatogenesis, microarray analysis was carried out using cDNA transcribed from total RNA derived from the dissected secondary palatal shelves of E13.5 *Tbx1*^*+/+*^; *Tbx1*^*+/−*^ and *Tbx1*^*−/−*^ embryos (*n* = 3 for each genotype).

After normalization and filtering of microarray data, comparison between mutant embryos and WT (Group A), heterozygous and WT (Group B) and mutant versus heterozygous (Group C) were performed (adj. *p* \< 0.1). The WebGestalt database was used to identify biological pathways associated with these differentially expressed transcripts \[[@CR57]\]. In Group A, 89 genes were identified to be differentially expressed in mutant compared to WT (adj. *p* \< 0.1, fold change 1.4). From these, 3 genes were upregulated, whereas the majority (*n* = 86) were downregulated (Table [1](#Tab1){ref-type="table"}). Group B includes differentially expressed genes arising from the comparison of heterozygous and WT palates (*n* = 400, adj. *p* \> 0.23). This group list was not considered statistically significant (adj. *p* \> 0.1) and therefore was not analysed further (Additional file [2](#MOESM2){ref-type="media"}). In Group C, 88 genes were identified to be differentially expressed in the mutant compared to heterozygote palate (adj. *p* \< 0.1, fold change 1.3). Amongst these, 11 genes were upregulated, whereas 77 were downregulated (Table [1](#Tab1){ref-type="table"}). In Group A, from the 89 genes that were searched, 9 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were identified (Fig. [3a](#Fig3){ref-type="fig"}). The most statistically enriched pathways (adj. *p* \< 0.1) were all associated with cardiac muscle physiology and included hypertrophic cardiomyopathy, cardiac muscle contraction, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and vascular smooth muscle contraction. Other pathways included phagosome and focal adhesion, tight junction and calcium signaling pathways and Alzheimer\'s disease (Additional file [3](#MOESM3){ref-type="media"}). In Group C, from the 88 genes that were searched, 10 KEGG pathways were identified (Fig. [3b](#Fig3){ref-type="fig"}). The most statistically enriched pathways (adj. *p* \< 0.1) were all also associated with cardiac muscle physiology, including hypertrophic and dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Other pathways included tight junction, calcium signalling, focal adhesion, neuroactive ligand-receptor interaction, phagosome and Alzheimer's disease pathways (Additional file [3](#MOESM3){ref-type="media"}). We were then interested to further identify the proportion of overlap amongst significantly differentially expressed genes between Groups A and C. (Fig. [4a](#Fig4){ref-type="fig"} \[[@CR58]\]). The two groups share 58 commonly expressed genes (Table [2](#Tab2){ref-type="table"}) when compared to WT and heterozygous; whereas 30 genes (Table [2](#Tab2){ref-type="table"}) were uniquely observed in Group A and 20 in Group C (Table [2](#Tab2){ref-type="table"}; adj. *P* \< 0.1). The WebGestalt database was used to provide insights into the mechanism of regulation associated with these 58 common gene transcripts. Adding to the above approach, heat map and dendogram clustering of the commonly expressed genes, as well as uniquely expressed genes in Group A and Group C (*n* = 99 genes) revealed transcriptional homogenicity between genotypes (Fig. [4b](#Fig4){ref-type="fig"}). Genes upregulated in mutants clearly clustered together and were shown to be downregulated in heterozygote and WT samples (red asterisks in Fig. [4b](#Fig4){ref-type="fig"}). In contrast, the downregulated transcriptome of mutant samples was shown to increase its expression in heterozygous and WT palates. Although statistical analysis revealed a non-significant expression pattern of Tbx1 heterozygous samples (adj. *p* values \> 0.1), heat map revealed a similarity in gene expression pattern between heterozygous and WT samples.Table 1Group comparison of *Tbx1*^*+/+*^, *Tbx1*^*+/−*^ and *Tbx1*^*−/−*^ palatal shelvesGene IDGene symbolDescriptionlogFCFold ChangeGroup A: Genes differentially expressed in mutant compared to WT palates14,462*Gata3*GATA binding protein 31,102,1566894*Wwp2*WW domain containing E3 ubiquitin protein ligase 20,641,5520466*Sin3a*transcriptional regulator, SIN3A (yeast)0,451,3727999*Fam3c*family with sequence similarity 3, member C−0,43−1,3523,945*Mgll*monoglyceride lipase−0,44−1,3622145*Tuba4a*tubulin, alpha 4A−0,46−1,3823,945*Mgll*monoglyceride lipase−0,46−1,3817286*Meox2*mesenchyme homeobox 2− 0,48− 1,39227929*Cytip*cytohesin 1 interacting protein−0,50−1,4121393*Tcap*titin-cap−0,50−1,4213426*Dync1i1*dynein cytoplasmic 1 intermediate chain 1−0,51−1,42231,633*Tmem119*transmembrane protein 119−0,52−1,4321953*Tnni2*troponin I, skeletal, fast 2−0,54−1,4627,273*Pdk4*pyruvate dehydrogenase kinase, isoenzyme 4−0,54−1,4613,038*Ctsk*cathepsin K−0,57− 1,48107765*Ankrd1*ankyrin repeat domain 1 (cardiac muscle)−0,57−1,4917533*Mrc1*mannose receptor, C type 1−0,59−1,5050796*Dmrt1*doublesex and mab-3 related transcription factor 1−0,59−1,5172713*Angptl1*angiopoietin-like 1−0,61−1,5313346*Des*desmin−0,67−1,5912862*Cox6a2*cytochrome c oxidase subunit VIa polypeptide 2−0,69−1,6156437*Rrad*Ras-related associated with diabetes−0,71−1,6412608*Cebpb*CCAAT/enhancer binding protein (C/EBP), beta−0,71−1,6414066*F3*coagulation factor III−0,74−1,6750768*Dlc1*deleted in liver cancer 1−0,74− 1,6712299*Cacng1*calcium channel, voltage-dependent, gamma subunit 1−0,74−1,6776,757*Trdn*triadin−0,76−1,6911475*Acta2*actin, alpha 2, smooth muscle, aorta−0,76− 1,6912292*Cacna1s*calcium channel, voltage-dependent, L type, alpha 1S subunit−0,76−1,7056012*Pgam2*phosphoglycerate mutase 2−0,79−1,7367951*Tubb6*tubulin, beta 6 class V−0,83−1,7811656*Alas2*aminolevulinic acid synthase 2, erythroid−0,84− 1,8019400*Rapsn*receptor-associated protein of the synapse−0,85−1,8022004*Tpm2*tropomyosin 2, beta−0,86−1,8212575*Cdkn1a*cyclin-dependent kinase inhibitor 1A (P21)−0,87−1,8317189*Mb*myoglobin−0,88−1,8511609*Agtr2*angiotensin II receptor, type 2−0,90−1,8621384*Tbx15*T-box 15− 0,91− 1,8712955*Cryab*crystallin, alpha B−0,92−1,8912955*Cryab*crystallin, alpha B−0,92−1,8950795*Sh3bgr*SH3-binding domain glutamic acid-rich protein−0,92−1,8917930*Myom2*myomesin 2−0,95−1,9312180*Smyd1*SET and MYND domain containing 1−0,96−1,9459058*Bhlhe22*basic helix-loop-helix family, member e22−0,96−1,9526465*Zfp146*zinc finger protein 146−1,01−2,0112391*Cav3*caveolin 3−1,02−2,0265086*Lpar3*lysophosphatidic acid receptor 3−1,06−2,09170812*Ahsp*alpha hemoglobin stabilizing protein−1,09−2,1314,077*Fabp3*fatty acid binding protein 3, muscle and heart−1,10−2,1511443*Chrnb1*cholinergic receptor, nicotinic, beta polypeptide 1 (muscle)−1,11−2,1617929*Myom1*myomesin 1−1,14−2,2021953*Tnni2*troponin I, skeletal, fast 2−1,16−2,24244954*Prss35*protease, serine 35−1,19−2,2969253*Hspb2*heat shock protein 2−1,20−2,2921957*Tnnt3*troponin T3, skeletal, fast−1,23−2,3514619*Gjb2*gap junction protein, beta 2−1,24−2,3613009*Csrp3*cysteine and glycine-rich protein 3−1,30−2,4612,350*Car3*carbonic anhydrase 3−1,37−2,5956069*Il17b*interleukin 17B−1,37−2,5911811*Apobec2*apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2−1,43−2,6911937*Atp2a1*ATPase, Ca++ transporting, cardiac muscle, fast twitch 1−1,46−2,7666139*Tmem8c*transmembrane protein 8C−1,48−2,7851801*Ramp1*receptor (calcitonin) activity modifying protein 1−1,56−2,9424131*Ldb3*LIM domain binding 3−1,56−2,9416545*Kera*keratocan−1,81−3,51140781*Myh7*myosin, heavy polypeptide 7, cardiac muscle, beta−1,81−3,5121828*Thbs4*thrombospondin 4−1,91−3,7513380*Dkk1*dickkopf homolog 1 (*Xenopus laevis*)− 1,94−3,8321955*Tnnt1*troponin T1, skeletal, slow−1,95−3,8758916*Myot*myotilin−1,98−3,9517928*Myog*myogenin−2,04−4,1221380*Tbx1*T-box 1− 2,06−4,1653311*Mybph*myosin binding protein H−2,06−4,1621952*Tnni1*troponin I, skeletal, slow 1−2,26−4,7912,350*Car3*carbonic anhydrase 3−2,31−4,9766402*Sln*sarcolipin−2,40−5,2811472*Actn2*actinin alpha 2−2,40−5,2917896*Myl4*myosin, light polypeptide 4−2,44−5,4321956*Tnnt2*troponin T2, cardiac−2,53−5,7711464*Actc1*actin, alpha, cardiac muscle 1−2,56−5,9066106*Smpx*small muscle protein, X-linked−2,61−6,1121924*Tnnc1*troponin C, cardiac/slow skeletal−2,67−6,3517901*Myl1*myosin, light polypeptide 1−2,76−6,7621925*Tnnc2*troponin C2, fast−2,77−6,8317907*Mylpf*myosin light chain, phosphorylatable, fast skeletal muscle−2,88−7,3521956*Tnnt2*troponin T2, cardiac−2,92−7,5711459*Acta1*actin, alpha 1, skeletal muscle−3,10−8,6017883*Myh3*myosin, heavy polypeptide 3, skeletal muscle, embryonic−3,22−9,2915,891*Ibsp*integrin binding sialoprotein−3,51−11,36Group C: Genes differentially expressed in mutant compared to heterozygous palates12,846*Comt*catechol-O-methyltransferase1,02,174,374*Clec16a*C-type lectin domain family 16, member A0,81,854153*Rasa4*RAS p21 protein activator 40,71,666894*Wwp2*WW domain containing E3 ubiquitin protein ligase 20,61,518,155*Pnoc*prepronociceptin0,61,556,538*Klk11*kallikrein related-peptidase 110,51,480904*Dtx3*deltex 3 homolog (Drosophila)0,51,4212,127*Proser1*proline and serine rich 10,51,4108655*Foxp1*forkhead box P10,41,476501*Commd9*COMM domain containing 90,41,414809*Grik5*glutamate receptor, ionotropic, kainate 5 (gamma 2)0,41,319280*Ptprs*protein tyrosine phosphatase, receptor type, S−0,3−1,318,008*Nes*nestin−0,4−1,327999*Fam3c*family with sequence similarity 3, member C−0,4−1,313426*Dync1i1*dynein cytoplasmic 1 intermediate chain 1−0,4−1,365114*Vps35*vacuolar protein sorting 35−0,5−1,421393*Tcap*titin-cap−0,5−1,417286*Meox2*mesenchyme homeobox 2− 0,5− 1,417286*Meox2*mesenchyme homeobox 2− 0,5− 1,472713*Angptl1*angiopoietin-like 1−0,5−1,467405*Nts*neurotensin−0,6− 1,511,303*Abca1*ATP-binding cassette, sub-family A (ABC1), member 1−0,6−1,521812*Tgfbr1*transforming growth factor, beta receptor I−0,6−1,515,366*Hmmr*hyaluronan mediated motility receptor (RHAMM)−0,6−1,511,733*Ank1*ankyrin 1, erythroid−0,6−1,521412*Tcf21*transcription factor 21−0,6−1,550796*Dmrt1*doublesex and mab-3 related transcription factor 1−0,7−1,612862*Cox6a2*cytochrome c oxidase subunit VIa polypeptide 2−0,7−1,650768*Dlc1*deleted in liver cancer 1−0,7−1,656437*Rrad*Ras-related associated with diabetes−0,7−1,656012*Pgam2*phosphoglycerate mutase 2−0,7−1,667951*Tubb6*tubulin, beta 6 class V−0,7−1,611,870*Art1*ADP-ribosyltransferase 1−0,7−1,715375*Foxa1*forkhead box A1−0,7−1,711,475*Acta2*actin, alpha 2, smooth muscle, aorta−0,8−1,712292*Cacna1s*calcium channel, voltage-dependent, L type, alpha 1S subunit−0,8−1,719400*Rapsn*receptor-associated protein of the synapse−0,8−1,780,882,479*Lrrn1*leucine rich repeat protein 1, neuronal−0,8−1,717189*Mb*myoglobin−0,8−1,712299*Cacng1*calcium channel, voltage-dependent, gamma subunit 1−0,8−1,812955*Cryab*crystallin, alpha B−0,8−1,811609*Agtr2*angiotensin II receptor, type 2−0,9−1,8111,886,114*Cryab*crystallin, alpha B−0,9−1,817930*Myom2*myomesin 2−0,9−1,812180*Smyd1*SET and MYND domain containing 1−0,9−1,8170812*Ahsp*alpha hemoglobin stabilizing protein−0,9−1,950795*Sh3bgr*SH3-binding domain glutamic acid-rich protein−0,9−1,914066*F3*coagulation factor III−0,9−1,959058*Bhlhe22*basic helix-loop-helix family, member e22−1,0−2,012391*Cav3*caveolin 3−1,0−2,117929*Myom1*myomesin 1−1,1−2,126465*Zfp146*zinc finger protein 146−1,1−2,121384*Tbx15*T-box 15− 1,1−2,121384*Tbx15*T-box 15− 1,1−2,211443*Chrnb1*cholinergic receptor, nicotinic, beta polypeptide 1 (muscle)−1,1−2,221953*Tnni2*troponin I, skeletal, fast 2−1,2−2,269253*Hspb2*heat shock protein 2−1,2−2,213009*Csrp3*cysteine and glycine-rich protein 3−1,2−2,321957*Tnnt3*troponin T3, skeletal, fast−1,3−2,411937*Atp2a1*ATPase, Ca++ transporting, cardiac muscle, fast twitch 1−1,3−2,456069*Il17b*interleukin 17B−1,3−2,514619*Gjb2*gap junction protein, beta 2−1,5−2,811435*Chrna1*cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)−1,5−2,811811*Apobec2*apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2−1,5−2,924131*Ldb3*LIM domain binding 3−1,6−3,017927*Myod1*myogenic differentiation 1−1,6−3,166139*Tmem8c*transmembrane protein 8C−1,7−3,221828*Thbs4*thrombospondin 4−1,8−3,4140781*Myh7*myosin, heavy polypeptide 7, cardiac muscle, beta−1,9−3,758916*Myot*myotilin−2,0−3,987,201,087*Tnnt1*troponin T1, skeletal, slow−2,0−3,917928*Myog*myogenin−2,1−4,353311*Mybph*myosin binding protein H−2,2−4,521952*Tnni1*troponin I, skeletal, slow 1−2,4−5,311,472*Actn2*actinin alpha 2−2,4−5,417896*Myl4*myosin, light polypeptide 4−2,5−5,566,402*Sln*sarcolipin−2,5−5,521,380*Tbx1*T-box 1−2,6−6,121956*Tnnt2*troponin T2, cardiac−2,6−6,266106*Smpx*small muscle protein, X-linked−2,7−6,511464*Actc1*actin, alpha, cardiac muscle 1−2,7−6,592,760,598*Tnnc1*troponin C, cardiac/slow skeletal−2,7−6,621925*Tnnc2*troponin C2, fast−2,8−6,917901*Myl1*myosin, light polypeptide 1−2,8−7,217907*Mylpf*myosin light chain, phosphorylatable, fast skeletal muscle−3,0−7,980,608,559*Tnnt2*troponin T2, cardiac−3,1−8,511,459*Acta1*actin, alpha 1, skeletal muscle−3,1−8,717883*Myh3*myosin, heavy polypeptide 3, skeletal muscle, embryonic−3,2−9,3Genes are listed based on fold changeFig. 3**a** Pathway analysis of genes differentially expressed in the *Tbx1* mutant secondary palate compared to WT (Group A); (**b**) pathway analysis of genes differentially expressed in the mutant secondary palate when compared to heterozygous (Group C): The pie chart depicts the number of assigned genes for each significantly enriched pathway. Data sets are illustrated as slices, the sizes of which are proportional to the number of genes implicated in each pathway. The ten pathways are listed and colour-coded on the rightFig. 4**a** Pairwise Venn diagram illustrating the comparison between gene sets from *Tbx1* mutant secondary palate compared to WT (Group A) and *Tbx1* mutant compared to heterozygous (Group C). The Venn diagram identified 58 common elements between Group A and Group C. Numbers in each section represent the number of genes. Transcripts utilized for the construction of the Venn diagram were statistically significant with adj. *p* values \< 0.1; (**b**) heat map (hierarchical clustering) of commonly expressed genes in Groups A and C, as well as uniquely expressed genes in Group A and C. Hierarchical cluster of 99 genes found to be differentially expressed in the 3 mutant, 3 heterozygous and 3 WT palatal samples. Transcripts utilized for the construction of clustering were statistically significant with adj. *p* values \< 0.1 except for heterozygous where adj. *p* values were \> 0.1. Visual inspection of heat map and dendogram clustering of the 9 samples revealed that all triplicates of the same genotype clustered together. Upregulated genes in mutants clustered together (red asterisks on left) and their pattern of expression could be visibly compared top heterozygous and WT samples. Each row represents a specific gene, and each column represents each genotype of the samples analysed. The colour represents the expression level of the gene. Red represents high expression, while blue represents low expression. The expression levels are continuously mapped on the colour scale provided at the top left of the figure. The dendrogram at the top of the matrix provides the degree of similarity between examined groups assessing the similarity between expressed genes and samples used for comparison. Note the similarity in gene expression between WT and *Tbx1* heterozygous transcriptsTable 2Table of genes originate from the comparison of Group A and Group C listsGene IDGene symbolDescriptionFifty-eight commonly expressed gene set list from Group A and Group C comparison16,545*Acta1*actin, alpha 1, skeletal muscle11,475*Acta2*actin, alpha 2, smooth muscle, aorta11,464*Actc1*actin, alpha, cardiac muscle 111,472*Actn2*actinin alpha 211,609*Agtr2*angiotensin II receptor, type 2170,812*Ahsp*alpha hemoglobin stabilizing protein11,811*Apobec2*apolipoprotein B mRNA editing enzyme, catalytic polypeptide 211,937*Atp2a1*ATPase, Ca++ transporting, cardiac muscle, fast twitch 159,058*Bhlhe22*basic helix-loop-helix family, member e2212,299*Cacng1*calcium channel, voltage-dependent, gamma subunit 112,299*Cav3*caveolin 311,443*Chrnb1*cholinergic receptor, nicotinic, beta polypeptide 1 (muscle)12,862*Cox6a2*cytochrome c oxidase subunit VIa polypeptide 212,955*Cryab*crystallin, alpha B12,955*Cryab*crystallin, alpha B13,009*Csrp3*cysteine and glycine-rich protein 350,768*Dlc1*deleted in liver cancer 150,796*Dmrt1*doublesex and mab-3 related transcription factor 114,066*F3*coagulation factor III14,619*Gjb2*gap junction protein, beta 269,253*Hspb2*heat shock protein 256,069*Il17b*interleukin 17B24,131*Ldb3*LIM domain binding 317,189*Mb*myoglobin17,286*Meox2*mesenchyme homeobox 253,311*Mybph*myosin binding protein H17,883*Myh3*myosin, heavy polypeptide 3, skeletal muscle, embryonic140,781*Myh7*myosin, heavy polypeptide 7, cardiac muscle, beta17,901*Myl1*myosin, light polypeptide 117,896*Myl4*myosin, light polypeptide 417,907*Mylpf*myosin light chain, phosphorylatable, fast skeletal muscle17,928*Myog*myogenin17,929*Myom1*myomesin 117,930*Myom2*myomesin 258,916*Myot*myotilin56,012*Pgam2*phosphoglycerate mutase 219,400*Rapsn*receptor-associated protein of the synapse56,437*Rrad*Ras-related associated with diabetes50,795*Sh3bgr*SH3-binding domain glutamic acid-rich protein66,402*Sln*sarcolipin66,106*Smpx*small muscle protein, X-linked12,180*Smyd1*myosin, heavy polypeptide 7, cardiac muscle, beta6899*Tbx1*T-box 112,384*Tbx15*T-box 1521,393*Tcap*titin-cap21,828*Thbs4*thrombospondin 466,139*Tmem8c*transmembrane protein 8C21,924*Tnnc1*troponin C, cardiac/slow skeletal21,925*Tnnc2*troponin C2, fast21,952*Tnni1*troponin I, skeletal, slow 121,953*Tnni2*troponin I, skeletal, fast 221,955*Tnnt1*troponin T1, skeletal, slow21,956*Tnnt2*troponin T2, cardiac21,956*Tnnt2*troponin T2, cardiac21,957*Tnnt3*troponin T3, skeletal, fast67,951*Tubb6*tubulin, beta 6 class V66,894*Wwp2*WW domain containing E3 ubiquitin protein ligase 226,465*Zfp146*zinc finger protein 146Thirty uniquely expressed gene set of Group A11,656*Alas2*aminolevulinic acid synthase 2, erythroid72,713*Angptl1*angiopoietin-like 1107,765*Ankrd1*ankyrin repeat domain 1 (cardiac muscle)12,292*Cacna1s*calcium channel, voltage-dependent, L type, alpha 1S subunit12,350*Car3*carbonic anhydrase 312,350*Car3*carbonic anhydrase 312,575*Cdkn1a*cyclin-dependent kinase inhibitor 1A (P21)12,608*Cebpb*CCAAT/enhancer binding protein (C/EBP), beta13,038*Ctsk*cathepsin K227,929*Cytip*cytohesin 1 interacting protein13,346*Des*desmin13,380*Dkk1*dickkopf homolog 1 (Xenopus laevis)13,426*Dync1i1*dynein cytoplasmic 1 intermediate chain 114,077*Fabp3*fatty acid binding protein 3, muscle and heart27,999*Fam3c*family with sequence similarity 3, member C14,462*Gata3*GATA binding protein 315,891*Ibsp*integrin binding sialoprotein65,086*Lpar3*lysophosphatidic acid receptor 323,945*Mgll*monoglyceride lipase23,945*Mgll*monoglyceride lipase17,533*Mrc1*mannose receptor, C type 127,273*Pdk4*pyruvate dehydrogenase kinase, isoenzyme 4244,954*Prss35*protease, serine 3551,801*Ramp1*receptor (calcitonin) activity modifying protein 120,466*Sin3a*transcriptional regulator, SIN3A (yeast)231,633*Tmem119*transmembrane protein 11921,953*Tnni2*troponin I, skeletal, fast 222,004*Tpm2*tropomyosin 2, beta76,757*Trdn*triadin22,145*Tuba4a*tubulin, alpha 4ATwenty uniquely expressed gene set of Group C11,303*Abca1*ATP-binding cassette, sub-family A (ABC1), member 111,733*Ank1*ankyrin 1, erythroid11,870*Art1*ADP-ribosyltransferase 111,435*Chrna1*cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)74,374*Clec16a*C-type lectin domain family 16, member A76,501*Commd9*COMM domain containing 912,846*Comt*catechol-O-methyltransferase80,904*Dtx3*deltex 3 homolog (Drosophila)108,655*Foxp1*forkhead box P114,809*Grik5*glutamate receptor, ionotropic, kainate 5 (gamma 2)56,538*Klk11*kallikrein related-peptidase 1116,979*Lrrn1*leucine rich repeat protein 1, neuronal17,286*Meox2*mesenchyme homeobox 217,927*Myod1*myogenic differentiation 167,405*Nts*neurotensin18,155*Pnoc*prepronociceptin212,127*Proser1*proline and serine rich 154,153*Rasa4*RAS p21 protein activator 421,384*Tbx15*T-box 1521,812*Tgfbr1*transforming growth factor, beta receptor IGenes are listed alphabeticallyAll genes described derived from the statistically significant groups (adj. *p* \< 0.1)

Confirmation of microarray data {#Sec6}
-------------------------------

For validation of the results obtained by microarray, RT-PCR was carried out using gene-specific primers (Applied Biosystems; Additional file [4](#MOESM4){ref-type="media"}) and the original RNA samples. In total, 27 genes from Group A and 28 genes from Group C were selected for gene expression verification (Table [3](#Tab3){ref-type="table"}). Changes in gene expression of these transcripts were normalized to that of ß-Actin. In both groups, 27 genes were commonly expressed (Table [3](#Tab3){ref-type="table"}; Fig. [5a](#Fig5){ref-type="fig"}); *Alas2* was uniquely present in Group A, whereas *Ank1* and *Chrna1* were uniquely present in Group C (Table [3](#Tab3){ref-type="table"}; Fig. [5b](#Fig5){ref-type="fig"}). All genes tested were confirmed as being significantly changed between WT-mutant and heterozygote-mutant except for *Ank1* (Group C; *p* = 0.102). In Group A, *Rapsn***,** *Sh3bgr*, *Tnnc2*, *Tnni2* and *Tnnt2* were the most downregulated genes; whereas in Group C, these were *Csrp3*, *Sh3bgr*, *Sln*, *Tnnc2*, *Tnni2*, *Myh7* and *Mylpf*.Table 3Validated genes from Groups A and CGene IDGene symbolDescriptionFold Change Group AFold change Group C*P* Value AnovaValidated genes commonly expressed in Groups A and C69253*Hspb2*heat shock protein 2−0.7−0.940.077617907*Mylpf*myosin light chain, phosphorylatable, fast skeletal muscle−1.1− 1.150.053140781*Myh7*myosin, heavy polypeptide 7, cardiac muscle, beta−0.97−1.240.047250795*Sh3bgr*SH3-binding domain glutamic acid-rich protein−1.77−1.410.043366402*Sln*sarcolipin−1.25− 1.360.037312955*Cryab*crystallin, alpha B−0.28− 0.560.033211443*Chrnb1*cholinergic receptor, nicotinic, beta polypeptide 1 (muscle)−0.74− 0.670.0317929*Myom1*myomesin 1−0.41− 0.880.029912180*Smyd1*SET and MYND domain containing 1−1.43−0.790.027712299*Cacng1*calcium channel, voltage-dependent, gamma subunit 1−0.91− 0.690.022119400*Rapsn*receptor-associated protein of the synapse−3.17−1.080.020221925*Tnnc2*troponin C2, fast−1.75− 1.280.018721384*Tbx15*T-box 15− 1.24− 0.590.017656437*Rrad*Ras-related associated with diabetes−0.69− 0.510.016812862*Cox6a2*cytochrome c oxidase subunit VIa polypeptide 2−1.01−0.940.013221828*Thbs4*thrombospondin 4−1.16−0.870.010321953*Tnni2*troponin I, skeletal, fast 2−1.75− 1.280.0094611811*Apobec2*apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2−0.97− 0.940.0047311609*Agtr2*angiotensin II receptor, type 2−0.56− 0.530.0036821956*Tnnt2*troponin T2, cardiac−1.67− 1.010.0032313009*Csrp3*cysteine and glycine-rich protein 3−1.58− 1.560.0030267951*Tubb6*tubulin, beta 6 class V−0.03− 0.590.0025121955*Tnnt1*troponin T1, skeletal, slow−1.04−0.820.0022621380*Tbx1*T-box 1− 0.80−0.870.00024214066*F3*coagulation factor III−0.81− 0.520.00023414619*Gjb2*gap junction protein, beta 2−0.92− 0.480.00000341Gene IDGene symbolDescriptionFold Change*P* Value (t-test)Validated gene uniquely expressed in Group A11656*Alas2*aminolevulinic acid synthase 2, erythroid−0.650.0062Validated genes uniquely expressed in Group C11,733*Ank1*ankyrin 1, erythroid−0.210.10211435*Chrna1*cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)−0.690.025Genes are listed based on *p* valueFig. 5Quantitative reverse transcriptase polymerase chain reaction verification of genes identified in Groups A and C following the microarray analysis. **a** Common genes significantly changed between both WT-mutant and heterozygote-mutant; (**b**) genes significantly changed only between WT-mutant (Group A); (**c**) genes significantly changed only between heterozygote-mutant (Group C)

Discussion {#Sec7}
==========

In the present study, functional explant assays and microarray analysis of gene expression was carried out in the palatal shelves of E13.5 mouse embryos WT, heterozygous or mutant for *Tbx1*. This was prompted by the knowledge that *Tbx1* is strongly expressed in epithelium of the palatal shelves throughout palatogenesis, mutant embryos demonstrate cleft palate with complete penetrance \[[@CR23], [@CR24], [@CR47], [@CR48]\] and the findings that *Tbx1* has multiple potential roles during normal palatal shelf elevation, elongation and adhesion \[[@CR47], [@CR48]\]. It is known that several regulatory networks underlie signaling between epithelium and mesenchyme during development of the secondary palate and we sought to discover potential genetic pathways disrupted during palatogenesis in the absence of *Tbx1*. We therefore focused our investigations at E13.5, just prior to the period of rapid growth and elevation \[[@CR45]\].

A key finding of this profile is the association between an absence of *Tbx1* function and altered expression (primarily downregulation) in a number of muscle-related genes within the shelves of the secondary palate. Developing mononuclear and binucleate myofibril-containing skeletal muscle cells are identifiable within the palatal shelves at E13 \[[@CR59]\] and findings of altered gene expression are perhaps not surprising, given the essential role of *Tbx1* during the development of branchiomeric musculature and somite-derived tongue muscles \[[@CR60]--[@CR62]\] and detectable expression in adult mouse muscle \[[@CR63], [@CR64]\]. In the embryo, Tbx1 activates the myogenic-determination genes myogenic factor 5 (*Myf5*) and myogenic differentiation (*MyoD*) in the mesodermal core of pharyngeal arches I and II \[[@CR61]\]. In addition, loss of *Tbx1* results in impairment of the onset of myogenic specification \[[@CR60]\] and Tbx1 synergizes with the myogenic factor Myf5 for initiation of myogenic cell fate \[[@CR65]\]. Our array failed to identify variation in *Myf5* and *MyoD*, but verified downregulation of *Myf7* at E13.5 in mutant palatal shelves. This finding suggests that Tbx1 functions upstream of myosin heavy chain 7 (Myh7) during palatal shelf formation and just prior to elevation, possibly as a myogenic factor. The presence of asymmetric expression patterns of myogenic regulatory factors in early first arch-derived muscles of *Tbx1* mutant embryos might explain the absence of *Myf5* and *MyoD* gene transcripts \[[@CR61]\]. In addition, both skeletal, smooth and non-muscle contractile systems have been identified and implicated in the process of normal palatal shelf elevation \[[@CR66], [@CR67]\]. A number of the downregulated genes identified have also been implicated in the process of skeletal and cardiac muscle contraction (*Tnni2, Tnnt1, Myh3, Myom1, Tnnc2*), which might reflect the lack of skeletal myogenic determination. Interestingly, microarray analysis of the early pharyngeal region of *Df1/*^*+*^*; Tbx1*^*+/−*^ embryos has previously demonstrated upregulation of *Tnnc2* \[[@CR68]\]. It cannot be discounted that other intrinsic contractile systems might also be disrupted in the secondary palate of *Tbx1* mutant mice. Indeed, changes in expression levels were also identified in genes associated with intracellular calcium signaling (*Atp2a1*, *Tnnc2*, *Cacna1s*, *Tnnc1*), which is known to mediate a number of important physiological processes of relevance to palatogenesis, including skeletal and smooth muscle contraction, apoptosis, cell motility and proliferation \[[@CR69]\].

After palatal shelf elevation, periderm cells joined by tight junctions are believed to function as a protective layer, preventing aberrant adhesions and playing an important role in mediating appropriate shelf adherence and epithelial differentiation \[[@CR70], [@CR71]\]. Loss of periderm is required at the tips of opposing palatal shelves and overall at sites where fusion is required \[[@CR71]\]. In *Tbx1* mutant mice, aberrant oral adhesions between tongue and palatal shelves have been observed \[[@CR48]\]. In the present study, the tight junction genes *Myh3*, *Mylpf*, *Myh7* and *Actn2* were downregulated in mutants at E13.5, suggesting a potential role for *Tbx1* in the normal function of tight junctions present within the palatal shelf epithelium.

Comparison between WT-mutant and heterozygous-mutant shelves revealed 58 genes commonly expressed in both groups. From these, 27 genes from Group A and 28 genes from Group C were selected for gene expression verification. Analysis revealed significant downregulation of 26 genes common to both groups (see Fig. [5a](#Fig5){ref-type="fig"}) with (*Alas2*) and (*Ank1, Chrna1*) individually downregulated in each group, respectively (see Fig. [5b](#Fig5){ref-type="fig"}). Statistical analysis revealed significant downregulation of all genes tested through RT-PCR with the exception of *Ank1* (*p* = 0.102; see Fig. [5b](#Fig5){ref-type="fig"}). Pathway analysis of these validated genes confirmed the associations between cardiac muscle contraction and calcium signaling, but also suggested links with dilated and hypertrophic cardiomyopathies. Although 22q11.2DS is commonly associated with conotruncal congenital heart defects, hypocalcemic dilated myocardiopathy has also been described in association with this condition \[[@CR72]\]. RT-PCR validation of the microarray analysis demonstrated no significant changes in gene expression between WT and heterozygous shelves, consistent with the normal palatogenesis seen in heterozygous embryos \[[@CR23]\].

Tbx1 is known to regulate both *Fgf8* and *Fgf10* expression in the early pharyngeal arches and cardiac outflow tract \[[@CR64]\] and influence the spatial distribution of *Fgf8* and *Bmp4* in the early mandible \[[@CR73]\]. It has also been suggested that *Fgf8* is significantly downregulated in the palatal shelf epithelium, whilst *Fgf10* is upregulated in the mesenchyme at E13.5 in *Tbx1* mutant embryos \[[@CR47]\]. However, we found no evidence of altered transcript levels associated with these genes in our array. This same report also demonstrated diminished hyaluronic acid (HA) in the palatal shelves of *Tbx1* mutant mice and whilst we found no obvious genetic links to this finding within our array, HA has been shown to induce matrix metalloproteinase 9 (*MMP9*) \[[@CR74]\], which was downregulated. However, whilst some members of the MMP family have been directly related to palatogenesis, at least in vitro; this did not include *MMP9* \[[@CR75]\].

In this microarray experiment, RNA was derived from whole dissected palatal shelves and therefore no formal distinction was made between changes in epithelial and mesenchymal gene activity. *Tbx1* is localized to the palatal shelf epithelium at E13.5, but is clearly able to influence signaling activity between epithelium and mesenchyme in the palate (Fig. [6](#Fig6){ref-type="fig"}). Indeed, the associations between Tbx1 function and muscle contraction and calcium signaling, both activities that take place in the early mesenchyme, are consistent with this. In addition, Tbx1 seems to act co-operatively with Shh signaling in the palate, through the repression of *Bmp4* and induction of *Pax9*. Interestingly, this co-operative activity would appear to be dependent upon Fgf signaling; *Shh* in the epithelium is dependent upon reciprocal signaling with Fgf10 in the mesenchyme \[[@CR54]\] and our explant studies demonstrate that *Tbx1* is also dependent upon Fgf signaling. Although it is currently not known which Fgf ligand is required or whether this is within the epithelium or mesenchyme, maintenance of epithelial *Tbx1* transcription is essential for normal palatogenesis. Conditional loss of *Tbx1* in either craniofacial mesenchyme \[[@CR48]\] or mesoderm \[[@CR76]\] does not result in cleft palate, in contrast to loss-of-function in the oral epithelium, which does \[[@CR48]\].Fig. 6Molecular associations linking *Tbx1* with Fgf and Shh signaling in the developing palate. *Tbx1* in the palatal shelf epithelium is downstream of Fgf signaling, the ligand/s and source (epithelium/ mesenchyme) are currently unknown. Shh-Fgf10-Fgfr2b epithelial-mesenchymal reciprocal signaling \[[@CR54]\] antagonizes *Bmp4* \[[@CR55]\] and induces *Pax9* indirectly through the induction of *Osr2* \[[@CR55], [@CR82]\]. We and others \[[@CR48]\] have demonstrated that Tbx1 acts to inhibit *Bmp4* and induce *Pax9*. It has been suggested that Tbx1 activity is required for *Fgf8* induction in the epithelium and *Fgf10* inhibition in the mesenchyme \[[@CR47]\]; however, we and others \[[@CR48]\] have found no evidence of this

Conclusions {#Sec8}
===========

We have conducted functional microarray analysis and PCR validation of gene expression in the developing secondary palate at E13.5 in the *Tbx1* mutant embryo. Differentially regulated genes were detected in the absence of this transcription factor. In the microarray, a total of 89 genes demonstrated differential expression in Group A and 88 genes in Group C (adj. *p* \< 0.1), whilst high-throughput quantitative RT-PCR confirmed 27 genes significantly changed between WT and mutant and 28 between heterozygote and mutant. Associations existed with cardiac muscle development, hypertrophic and dilated cardiomyopathy, tight junction and calcium signaling. These findings provide further evidence of a primary role for *Tbx1* during the process of palatogenesis.

Methods {#Sec9}
=======

Mice {#Sec10}
----

Breeding mice were maintained in ventilated cages on an alternating (12:12) light-dark cycle in the Biological Services Unit at King's College London. Time-mated *Tbx1* embryos were generated by inter-crossing *Tbx1*^*+/−*^ mice on a C57/Bl6 background \[[@CR23]\] such that noon of the day on which vaginal plugs were detected was considered as embryonic day (E) 0.5. Pregnant females were euthanized with cervical dislocation.

### Explant culture {#Sec11}

Secondary palatal shelves were carefully micro-dissected from E13.5 WT embryos and cultured for 24 h in the presence of cyclopamine or SU4502 as previously described \[[@CR77]\]. Briefly, explants were cultured using a modified Trowell technique at 37 °C in an atmosphere of 5% CO2 in serum-free Advanced DMEM/F12 (GibcoBRL) supplemented with 20 U/ml penicillin and streptomycin (GibcoBRL), 10% Fetal Bovine Serum (GibcoBRL), 50 mM transferrin (Sigma) and 150 μg/ml ascorbic acid (Sigma). SU5402 (Calbiochem) was diluted in medium from a 10 mM stock solution in DMSO and cyclopamine (Sigma) was diluted from a 20 mg/ml stock solution in ethanol and added to the culture medium at a final concentration of 75 μM for both inhibitors. A minimum of (*n* = 6) palatal shelves were used for each experiment.

### In situ hybridisation {#Sec12}

Wholemount digoxygenin and section ^35^S radioactive in situ hybridisation was carried out as previously described \[[@CR78]\]. Wholemount (*n* = 6 palatal shelves) and section (*n* = 3 embryos) images were photographed using Leica or Zeiss Axioscop microscopes, respectively. For radioactive in situ hybridisation, light and darkfield images were merged in Adobe photoshop CS. Plasmid cDNA was kindly provided by the following investigators: *Bmp4* (Brigid Hogan); *Fgf8* (Ivor Mason); *Fgf10; Fgfr2b* (David Rice); *Pax9* (Heiko Peters); *Ptch1* (Matthew Scott); *Shh* (Andy McMahon); *Sprty2* (M. Albert Basson), *Tbx1* (Peter Scambler).

### Tissue preparation and microarray analysis {#Sec13}

Secondary palatal shelves were carefully micro-dissected from E13.5 *Tbx1* WT, heterozygous or mutant embryos (3 embryos per genotype), stored as pairs from each embryo in RNA*later* (Ambion) and then homogenized using a blunt 20-guage needle to an RNase-free syringe. Total RNA was extracted from homogenate derived from each shelf pair using an RNeasy Isolation Kit (Qiagen). RNA quality was checked using an Agilent Bioanalyzer and quantified with spectrophotometry (NanoDrop ND-1000). In total, 9 sets of RNA were collected, each derived from paired secondary palatal shelves harvested from each embryonic genotype (giving 3 samples from each genotype).

### Microarray chip processing and data analysis {#Sec14}

The expression profiling analysis was carried out at the Franklin-Wilkins Building Genomics Facility, King's College London. Total RNA was reverse-transcribed and cRNA generated using the MessageAmp II-Biotin Enhanced cRNA Amplification Kit (Ambion). cRNA targets were then hybridized to the Affymetrix Mouse GeneChip microarray (MOE430_A\_2 GeneChip array), which is a single array containing 22,690 probe sets representing transcripts and variants from over 14,000 well characterized mouse genes. A single chip was used for each pair of palatal shelves per genotype, with hybridization and scanning of array chips carried out according to recommended protocols ([www.affymetrix.com](http://www.affymetrix.com)).

Microarray data were analysed by the implementation of Bioconductor packages in the programming language R. Intensity values of every chip were imported and evaluated with the packages *affy*, *simpleaffy* and *affyPLM*. Pre-processing, normalization and expression transformations were executed by the function *rma* of the *affy* package \[[@CR79]\]. Gene expressions were fitted to linear models and moderated t-statistics were calculated for specific comparisons using *lmfit* and *eBayes* functions of the *limma* package \[[@CR80]\]. *P*-values were adjusted for multiple testing with the Benjamini & Hochberg FDR method \[[@CR81]\], implemented within the *topTable* function of the *limma* package. Venn diagram and heatmap showing hierarchical clustering with complete linkage scaled by genes were constructed using the packages *VennDiagram* and *gplots* respectively. Microarray datasets have been submitted to the Gene Expression Omnibus (GEO) at NCBI (GSE37904).

### Functional annotation of differentially regulated gene sets {#Sec15}

In this study WEB-based GEne SeT AnaLysis Toolkit (WebGestalt, <http://www.webgestalt.org/option.php>, version 05/20/2014) was utilized to perform functional enrichment analysis on the data sets containing genes from the *Tbx1*^−/−^ versus WT shelves comparison (Group A), the *Tbx1*^−/−^ versus *Tbx1*^+/−^ shelves comparison (Group C) and the commonly expressed gene set of Group A and Group C. For each gene set, WebGestalt used the hypergeometric test to evaluate functional enrichment against predefined categories collected from KEGG. Statistical analysis was performed according to the current default settings.

### Validation with high throughput quantitative real-time RT-PCR and data analysis {#Sec16}

Candidate genes were validated with high-throughput real time quantitative RT-PCR using the same nine total RNA samples from the microarray screen. RNA was converted to first-strand cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems). Real time PCR assays were identified using Applied Biosystems UmapIt tool to map microarray probeset IDs to inventoried Taqman(r) assays. cDNA samples and assay master mixes were combined on 384-well real-time PCR plates (Applied Biosystems) using the Biomek FX liquid handling robot (Beckman Coulter). A total of nine 384-well plates were used. Each cDNA sample was combined with each gene primer sequence and replicated across four wells, giving four technical replicates for each PCR reaction. Each 384-well plate contained a column for water (no-template control) and ß-Actin (house-keeping gene/endogenous control for data normalization) with a 7900HT Quantitative PCR machine (Applied Biosystems) used for the PCR reaction. The qPCR data was analysed using RQ manager (Applied Biosystems) and Microsoft Excel. The RQ manager uses CT values from the qPCR reaction along with normalisation of the data to provide Relative Quantification (RQ) values (RQ = 2--ΔΔCT) for gene expression. For the 26 commonly expressed genes from Group A and C, ANOVA was used to detect statistically significant differences in Relative Quantification group means between WT, heterozygous and mutant genotypes. The differences in Relative Quantification for the uniquely expressed Alas2 in Group A and Ank1, Chrna1 genes between the WT and the MUT (Group C) were analysed by using t-test. All the above statistical analyses and graphs designs were performed in R. For the graphs, the ggplot2 package was used (see Fig. [5](#Fig5){ref-type="fig"}). From the 29 genes selected from microarray analysis, 28 individual genes showed significant changes in expression levels in the mutant compared to WT and/or heterozygote (*P* value \< 0.05), whereas only *Agtr2* from Group C was shown to be non-statistically significant (*P* value = 0.102), in qPCR.

Additional files
================

 {#Sec17}

Additional file 1:*Tbx1 lacZ* reporter expression in the developing murine palate. (A) E12.5; (B) E13.5; (C) E14.5; (D) E15.5. *Tbx1* is expressed in epithelium of the primary (yellow arrowhead) and secondary palate (white arrowhead) with expression persisting in these regions during the process of fusion (orange and pink arrowheads, respectively). Expression is also seen in the maxillary incisor tooth germs (green arrowhead), maxillary molar tooth germs (red arrowhead) and palatal rugae (black arrows). (TIF 2146 kb) Additional file 2:List of genes differentially expressed in WT compared to heterozygous palates (*n* = 400) (Group B). (XLSX 33 kb) Additional file 3:KEGG pathway analysis. (XLSX 11 kb) Additional file 4:Quantitative RT-PCR primer/probe list. This table contains a complete list of the 63 primers/ probes used in the real-time quantitative RT-PCR analysis of gene expression in the developing palate of *Tbx1* mice. (DOCX 90 kb)

22q11.2DS

:   22q11.2 deletion syndrome

Bmp

:   Bone morphogenetic protein

CAFS

:   Conotruncal anomaly face

DGS

:   DiGeorge syndrome

Fgf

:   Fibroblast growth factor

Fgfr2b

:   Fibroblast growth factor receptor 2b

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

*Myf5*

:   Myogenic factor 5

Myh7

:   Myosin heavy chain 7

*MyoD*

:   Myogenic differentiation

OFT

:   Outflow tract

Pax9

:   Paired box 9

Ptch1

:   Patched 1

RT-PCR

:   Reverse Transcription Polymerase Chain Reaction

Shh

:   Sonic hedgehog

Smad

:   Mothers against decapentaplegic homologue

Spry2

:   Sprouty 2

*TBX1*

:   Transcription factor-encoding T-Box 1

VCFS

:   Velocardiofacial syndrome

WT

:   Wild Type
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